thought call
solid focu growth beyond
thought pfizer result rais guidanc solid
even impact final loe lyrica seen quarter q/q
inde number key product perform well despit uncertainti
warn jak class q/q ibranc high share new competitor
q/q vyndaqel new us launch q/q manag didnt provid
guidanc solidifi expect revenu compound-annual-growth-rate
remainco busi inde differenti among biopharma peer concern
profil inclus posit readout adjuv ibranc well
prevnar adult former set signific
binari event next year addit suspect impact recent deal
mostli upjohn/mylan fulli assum consensu non-gaap ep
bloomberg versu previous henc premium multipl
estim peer increas concern loe period
risk binari event ibranc adjuv data dont think risk/reward profil
attract current level maintain neutral rate howev
rais po base result better revenu assumpt
pipelin updat announc posit phase safeti result prevnar
pediatr popul phase trial adult fulli enrol data expect
earli announc posit result phase trial somatrogon long act
genotropin expect begin dose hemophilia gene therapi patient phase
trial announc posit top-lin result second phase pivot studi
abrocitinib atop dermat recent submit snda interim analysi result
phase beacon trial fda review biosimilar launch date expect
zirabev dec ruxienc jan trazimera feb
model chang updat model forecast
revenu new
non-gaap ep estim vs respect
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
loe loss exclus
acip advisori committe
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global biopharmaceut compani
diversifi portfolio product pipelin
candid one largest pharma
compani world measur market
capit revenu compon
jone industri averag
shed low growth busi divis
upjohn consum focus higher
growth innov busi compani look
return growth serv base
year revenu grow howev key
pipelin win necessari second wave
put growth risk
neutral await transact
close pipelin matur off-set
million
net incom sharehold
remainco base blend averag dcf analysi
price-to-earnings multipl base larg cap global therapeut group dcf use
wacc termin valu intrins valu price-to-earnings analysi
assum multipl ep estim vs peer larg reflect
higher growth expect yield intrins valu support po
downsid risk sale downsid would expect share declin upcom data
prevnar ibranc posit inabl pipelin overcom patent loe
 transact perceiv valu destruct
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
